Xeris Biopharma Holdings (XERS) EPS (Weighted Average and Diluted): 2021-2025
Historic EPS (Weighted Average and Diluted) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $0.00.
- Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) rose 103.18% to $0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.10, marking a year-over-year increase of 78.07%. This contributed to the annual value of -$0.37 for FY2024, which is 17.78% up from last year.
- According to the latest figures from Q3 2025, Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) is $0.00, which was up 134.96% from -$0.01 recorded in Q2 2025.
- Xeris Biopharma Holdings' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.00 during Q3 2025, with a 5-year trough of -$0.44 in Q4 2021.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.08, with a median of -$0.09 in 2023.
- As far as peak fluctuations go, Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) dropped by 22.22% in 2024, and later soared by 103.18% in 2025.
- Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.44 in 2021, then spiked by 77.27% to -$0.10 in 2022, then increased by 10.00% to -$0.09 in 2023, then soared by 66.67% to -$0.03 in 2024, then soared by 103.18% to $0.00 in 2025.
- Its EPS (Weighted Average and Diluted) was $0.00 in Q3 2025, compared to -$0.01 in Q2 2025 and -$0.06 in Q1 2025.